Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Sredni

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Current Eye Research|August 1, 1994
Ocular inflammation stimulated by the immunomodulator AS101 [ammonium trichloro(dioxyethelene-O-O') tellurate]K Dastgheib, N Hikita, B Sredni, et al.
Journal of the National Cancer Institute|September 18, 1996
Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101B Sredni, T Tichler, A Shani, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1993
Tubulointerstitial nephritis and uveitis: association with suppressed cellular immunityU Gafter, Y Kalechman, D Zevin, et al.
The British Journal of Dermatology|September 24, 2008
Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: assessment of its safety and efficacyM Friedman, I Bayer, I Letko, et al.
Virus Research|March 27, 2012
In vitro and in vivo activity of AS101 against West Nile virus (WNV)V Indenbaum, H Bin, D Makarovsky, et al.
The British Journal of Dermatology|February 5, 2008
Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101G M Frei, M Kremer, K-M Hanschmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposideB Sredni, M Albeck, T Tichler, et al.
Immunology Letters|December 1, 1994
Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101B Sredni, Z Rosenthal-Galili, H Michlin, et al.
Nature|November 12, 1987
A new immunomodulating compound (AS-101) with potential therapeutic applicationB Sredni, R R Caspi, A Klein, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1983
Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF)E Kedar, B L Ikejiri, T Timonen, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Current Eye Research|August 1, 1994
Ocular inflammation stimulated by the immunomodulator AS101 [ammonium trichloro(dioxyethelene-O-O') tellurate]K Dastgheib, N Hikita, B Sredni, et al.
Journal of the National Cancer Institute|September 18, 1996
Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101B Sredni, T Tichler, A Shani, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1993
Tubulointerstitial nephritis and uveitis: association with suppressed cellular immunityU Gafter, Y Kalechman, D Zevin, et al.
The British Journal of Dermatology|September 24, 2008
Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: assessment of its safety and efficacyM Friedman, I Bayer, I Letko, et al.
Virus Research|March 27, 2012
In vitro and in vivo activity of AS101 against West Nile virus (WNV)V Indenbaum, H Bin, D Makarovsky, et al.
The British Journal of Dermatology|February 5, 2008
Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101G M Frei, M Kremer, K-M Hanschmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposideB Sredni, M Albeck, T Tichler, et al.
Immunology Letters|December 1, 1994
Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101B Sredni, Z Rosenthal-Galili, H Michlin, et al.
Nature|November 12, 1987
A new immunomodulating compound (AS-101) with potential therapeutic applicationB Sredni, R R Caspi, A Klein, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1983
Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF)E Kedar, B L Ikejiri, T Timonen, et al.
Pageof 10